🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Great to hear insights from Jay Bradner, M.D. in conversation with Ross Levine, chair of Memorial Sloan Kettering Cancer Center, on how academic & industry researchers can cooperate in translational research and drug discovery. #CancerInnovation #CancerResearch #MarkSymposium

Dr. Alexandra Joyner, a developmental biologist at MSK, is hanging up her lab coat following an illustrious 40-plus-year career. “Dr. Joyner is a great example of a scientist trained in a fundamental discipline...who, like many others at the Sloan Kettering Institute (SKI),

Telemedicine is redefining pain management—enhancing access, improving care, and cutting overheads. Dr. Amitabh Gulati of Memorial Sloan Kettering Cancer Center breaks down the latest advances! 📖 Read the full story → tinyurl.com/4tbtacem #PainMedicine #Telehealth #PainConnect2025

New in Nature Communications: MSK's Kentsis Research Group & collaborators identified a rare population of stem cells responsible for disease persistence & therapy resistance in acute myeloid leukemia (#AML), which could help improve treatment strategies: go.nature.com/4hZXTXQ

Dr. Ross Firestone's (Memorial Sloan Kettering Cancer Center) presentation at #DAVAWhistler focused on sequencing strategies for bispecific and CAR-T in MM, grounded in evolving resistance mechanisms. How prior BCMA-targeted therapies may influence treatment response was discussed. #Myeloma #Oncology

I’m pleased to share our summary of the clinical evidence on the use of TKIs and SRS in EGFR or ALK+ NSCLC! We need better biomarkers to select patients for treatment de-escalation. JAMA Oncology Memorial Sloan Kettering Cancer Center Memorial Sloan Kettering Radiation Oncology jamanetwork.com/journals/jamao…

We sat down with @mskcancercenter's Dr. Richard Koche and Dr. Iestyn Whitehouse to learn how epigenetics is revolutionizing rare cancer treatment and why Cycle for Survival funding is so important for their research. Help us continue this vital work: bit.ly/4liTKkS

The U.S. FDA has expanded approval for 177Lu-PSMA-617 (Pluvicto), a treatment for patients with #prostatecancer, based on results from a phase 3 trial led by researchers at MSK. More patients can now benefit from the treatment. “This type of precision medicine is a game changer

Dr. Richard Wong, a head and neck surgeon at MSK, was able to preserve one international patient's singing voice through a thyroid isthmectomy, a somewhat rare surgical procedure. “We create an individualized treatment plan for each patient,” Dr. Wong says, “and it’s led to a

Join the Memorial Sloan Kettering Cancer Center (MSK) Direct Benefits Leaders’ Summit on Wednesday, May 7 to hear discussions about screening trends among employers and health plans, the role of genetics in personalizing screening recommendations, and more. There will also be

.@mskcancercenter and City of Hope researchers develop test using machine learning to help predict immunotherapy response in lymphoma  cancerletter.com/clinical-round…

Cool study by Memorial Sloan Kettering Cancer Center: A mutation present in all microglia/myeloid cells across the brain drives inflammation & pathology only in cerebellum & brainstem! First discovered in 🧑‍🤝‍🧑, this holds true in 🐭 Great example of how region is a key factor for CNS pathology 🧠🔬

📺 In a new interview with Yelena Y. Janjigian MD of Memorial Sloan Kettering Cancer Center, she reviews the design and outcomes of KEYNOTE-811 and how its positive results led to the FDA approval of #pembrolizumab for HER2-positive gastric or GEJ cancers: buff.ly/6rjqDeP

Kicking off the Memorial Sloan Kettering Cancer Center #mmsm Myeloma Spring Retreat on campus with this vibrant and talented crew.

Dr. Viviane Tabar and Dr. Lorenz, physician-scientists at MSK, have developed a treatment for #Parkinson’s disease that involves creating nerve cells from embryonic stem cells and transplanting them into patients. Early results show the treatment is safe and may improve

Join experts from MSK for the 14th Annual Educational Workshop for Patients and Families with #LynchSyndrome held virtually on Tuesday, May 6 from 6-8:30pm. Register here: bit.ly/3EsxdBp

In a study published in Immunity, MSK's Joseph Sun Lab and Dr Becs found that fasting can supercharge the immune system's “natural killer” cells, a type of white blood cells that can kill #cancer cells. Researchers are optimistic that what they’re learning in animal

Early results from an MSK study shows a treatment for #Parkinson’s disease that involves creating nerve cells from embryonic stem cells and transplanting them into patients is safe and may improve Parkinson’s symptoms. Read more via NPR: n.pr/43ZW1v6

Truly groundbreaking research with immediate benefits to patients from Lorenz Viviane Tabar Memorial Sloan Kettering Cancer Center and colleagues at BlueRock Therapeutics